In terms of medication use, patients with COVID-19 were less likely to receive ACE inhibitors or ARBs (43.5% vs. 61.5%; p < 0.001), beta-blockers (47.5% vs. 58.6%; p = 0.026), and insulin (19.8% vs. 36.3%; p < 0.001), but more likely to be treated with vitamin D (36.2% vs. 20.1%; p < 0.001), Eltroxin (20.9% vs. 9.5%; p < 0.001), antipsychotics (36.2% vs. 10.3%; p < 0.001), and antidepressants (28.2% vs. 41.8%; p = 0.004). This evidence concerns the gene ACE and COVID-19.